

[illegible]

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
KS	B14	WO 03/027076	A2 & A3		SOLVAY PHARMACEUTICALS B.V.	04-02-2003	
KS	B15	WO 03/007887	A2 & A3		MERCK & CO., INC.	01-30-2003	
Examiner Signature		Date Considered /Kamal Saeed/				06/23/2000	

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				Application Number	Not yet known
				Filing Date	Herein
				First Name Inventor	Alexander Mayweg
				Group Art Unit	1626
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	21554

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
KS	A1	5624941		Sanofi	04-29-1997
KS	A2	3940418		G.D. Searle & Co.	02-24-1976
KS	A3	5596106		Eli Lilly and Company	01-21-1997

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)		
KS	B1		WO0015609		Aventis Pharma S.A.	03-23-2000
	B2		WO0164634		Aventis Pharma S.A.	09-07-2001
	B3		WO0228346		Aventis Pharma S.A.	04-11-2002
	B4		WO0164632		Aventis Pharma S.A.	09-07-2001
	B5		WO0164633		Aventis Pharma S.A.	09-07-2001
	B6		WO0170700		Solvay Pharmaceuticals B.V.	09-27-2001
	B7		WO0132663		Sanofi-Synthelabo	05-10-2001
	B8		WO0046209		Sanofi-Synthelabo	08-01-2000
	B9		WO9719063		Sanofi	05-29-1997
	B10		EP658546		Sanofi-Synthelabo	06-21-1995
	B11		EP656354		Sanofi	06-07-1995
	B12		EP576357		Sanofi	12-29-1993
KS	B13		WO9602248		Eli Lilly and Company	02-01-1996
Examiner Signature		/Kamal Saeed/				06/23/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)			<b>Substitute for form 1449A/PTO</b>		
			<b>Complete if Known</b>		
			Application Number	Not yet known	
			Filing Date	Herein	
			First Name Inventor	Alexander Mayweg	
			Group Art Unit	1626	
			Examiner Name		
Sheet	2	Of	2	Attorney Docket Number	21554

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
KS ↓ KS	C1	PACHECO, M., ET AL., Aminoalkylindoles: Actions on Specific G-Protein-Linked Receptors, Journal of Pharmacology and Experimental Therapeutics, 1991, pp. 170-183, v. 257(1)	
	C2	CASIANO, F.M., ET AL., Putative Aminoalkylindoles (AAI) Antagonists, Problems of Drug Dependence 1990: Proceedings of the 52 <sup>nd</sup> Annual Scientific Meeting The Committee on Problems of Drug Dependence, 1991, pp. 295-296, v. 105	
	C3	HOSOHATA, K., ET AL., AM630 is a Competitive Cannabinoid Receptor Antagonist in the Guinea Pig Brain, Life Sciences, 1997, pp. 115-118, v. 61(9)	
	C4	PERTWEE, R., ET AL., AM630, A Competitive Cannabinoid Receptor Antagonist, Life Sciences, 1995, pp. 1949-1955, v. 56(23/24)	
	C5	FELDER, C.C., ET AL., LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation, Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 291-297, v. 284(1)	
	C6	KANYONYO, M. ET AL., 3-Alkyl-(5,5'-Diphenyl) Imidazolidinediones As New Cannabinoid Ligands, Bioorganic & Medicinal Chemistry Letters, 1999, pp.2233-2236, v. 9	
	C7	OOMS, F., ET AL., Exploration of the Pharmacophore of 3-Alkyl-5-Arylimidazolidinediones as New CB <sub>1</sub> Cannabinoid Receptor Ligands and Potential Antagonists: Synthesis, Lipophilicity, Affinity, and Molecular Modeling, J. Med. Chem., 2002, pp.1748-1756, v. 45(9)	
Examiner Signature	/Kamal Saeed/		DATE CONSIDERED
			06/23/2006

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

137401